Drug Trial Radar · NCT04971395
Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jun 25, 2021
Primary completion
Mar 18, 2022
Study completion Mar 18, 2022
Sponsor
- Lead sponsor
- Xentria, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, double-blind, placebo-controlled, first-in-human, single intravenous (IV) infusion of XTMAB-16 (formerly referred to as KBMAB-16) in normal healthy male and female participants.
Conditions
- Healthy Participants
Interventions
PlaceboDrug
Single dose of 2 or 4 mg/kg
XTMAB-16 2 mg/kgDrug
Single dose of 2 mg/kg
XTMAB-16 4mg/kgDrug
Single dose of 4 mg/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participant With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to day 71
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MedStar Harbor Hospital
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.